Merxin launches MRX001: a generic blister multidose dry powder inhaler.

Merxin launches MRX001: a generic blister multidose dry powder inhaler.

November 28, 2016

Congratulations to the the team at Merxin who launches MRX001 today, its generic blister based multidose dry powder inhaler.

MRX001 is a true substitutable version of the world’s most successful multidose blister dry powder inhalation device. It is targeted to support 505j substitutable generic inhaler applications. It enables developers to file generic versions of popular DPI combination products quickly and reliably such as fluticasone+salmeterol. MRX001 can also be used for any molecules and combinations for inhaled delivery, such as tiotropium multidose, formoterol+budesonide etc. MRX001 is supplied to product developers as an “off the shelf” solution. MRX001 offers a FASTER, LOWER COST and LOWER RISK development route built on a proven platform.

Merxin will be at DDL27 in Edinburgh 1-9 December 2017. Do get in touch to arrange a meeting and learn about the Merxin device portfolio. For more information about MRX001, send us an email at info@merxin.com or get in touch via our website: merxin.com/contact-us.

About Merxin (www.merxin.com): Merxin is a generic medical device company that supplies generic inhalation devices “off the shelf and ready to use”. By supplying standardised off-the-shelf devices, Merxin provides clients with a lower cost and lower risk route to market. The Merxin team has a thorough understanding of medical device and pharmaceutical product development: www.merxin.com.